- Home
- ADV vs VYGR Comparison
ADV vs VYGR Comparison
Compare ADV & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | VYGR |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | 69000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 194.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADV | VYGR |
|---|---|---|
| Price | $0.53 | $4.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 761.1K | 524.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | $71.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $2.65 |
| 52 Week High | $2.53 | $5.55 |
Technical Indicators
Market Signals| Indicator | ADV | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 60.60 |
| Support Level | N/A | $3.73 |
| Resistance Level | $0.97 | $4.32 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 11.15 | 78.91 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.